SNOANasdaqSurgical & Medical Instruments & ApparatusFiscal year ends March 31

Sonoma Pharmaceuticals, Inc.

Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$1.12+0.00 (0.00%)

Close on Oct 19, 2026

Community

Notes and questions about Sonoma Pharmaceuticals from other investors

Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Parsed from the XBRL in Sonoma Pharmaceuticals's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-20 reverse split on Nov 7, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is SNOA.

Revenue growth47.0% · median 4.4%

Gross margin38.9% · median 49.3%

Operating margin-6.4% · median -24.5%

Net margin-10.3% · median -27.6%

Advertisement
300 × 250